<DOC>
	<DOCNO>NCT00072007</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cladribine , use different way stop cancer cell divide stop grow die . Monoclonal antibody , rituximab , locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Combining cladribine rituximab may kill cancer cell . PURPOSE : This phase II trial study well give cladribine rituximab remission induction therapy together rituximab stem cell mobilization treat patient chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Cladribine Rituximab Remission Induction Therapy Followed By Rituximab Stem Cell Mobilization Treating Patients With CLL</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine efficacy tolerability cladribine rituximab remission induction therapy patient chronic lymphocytic leukemia . - Determine complete remission rate patient treat regimen . Secondary - Determine good partial remission rate nodular partial remission rate patient treat regimen . - Determine toxicity regimen , term hemotoxicity infection rate , patient . - Determine efficacy vivo purge rituximab measure immunophenotyping patient . - Determine feasibility stem cell harvest patient treatment induction therapy regimen vivo purge rituximab . OUTLINE : This multicenter study . - Remission induction : Patients receive cladribine subcutaneously ( SC ) day 1-5 . During course 2-4 , patient also receive rituximab IV day 1 . Treatment repeat every 28 day 4 course absence unacceptable toxicity . If unacceptable toxicity persists , patient receive rituximab alone . Patients achieve complete remission ( CR ) , good partial remission ( VGPR ) , nodular partial remission ( NPR ) receive CHOP chemotherapy comprise cyclophosphamide IV , doxorubicin IV , vincristine IV day 1 oral prednisone day 1-5 . Treatment repeat every 21 day 4 course patient achieve CR , VGPR , NPR . Patients achieve CR , VGPR , NPR proceed stem cell mobilization vivo purge . - Stem cell mobilization vivo purging : Beginning 8-10 week first day last course remission induction CHOP , patient receive rituximab IV day 1 8 , cyclophosphamide IV 4 hour day 2 , filgrastim ( G-CSF ) SC daily begin day 4 continue last day apheresis . Patients undergo apheresis day 11-14 . PROJECTED ACCRUAL : A total 17-41 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis Bcell chronic lymphocytic leukemia ( CLL ) CD5 positive CD23 positive Binet stage B , C , progressive A Newly diagnose disease OR 1 prior alkylating agent regimen ( e.g. , chlorambucil cyclophosphamide without prednisone ) PATIENT CHARACTERISTICS : Age 18 65 Performance status WHO 02 Life expectancy Not specify Hematopoietic No autoimmune hemolytic anemia No immune thrombocytopenia Hepatic Bilirubin great 1.5 time upper limit normal ( ULN ) Alkaline phosphatase great 2.5 time ULN* AST ALT great 2.5 time ULN* NOTE : *Unless clearly related CLL liver involvement Renal Creatinine clearance great 50 mL/min Cardiovascular Ejection fraction least 50 % No severe heart failure No unstable angina pectoris No significant arrhythmia require chronic treatment No myocardial infarction within past 3 month Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 12 month study participation HIV negative No active infection No positive Coombs ' test No history significant neurologic psychiatric disorder , include psychotic disorder dementia No seizure disorder No malignancy within past 5 year except nonmelanoma skin cancer adequately treat carcinoma situ cervix No prior allergic reaction hypersensitivity study drug attribute compound similar chemical biological composition study drug study agent No uncontrolled diabetes mellitus No gastric ulcer No active autoimmune disease No alcohol drug abuse No concurrent serious underlie medical condition would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics No prior purine analog ( e.g. , cladribine fludarabine ) Endocrine therapy Not specify Radiotherapy No concurrent radiotherapy Surgery Not specify Other More 30 day since prior clinical trial participation No concurrent experimental drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
</DOC>